Loading organizations...
AMSilk is an industrial biotechnology company based in Neuried, Germany, that produces synthetic silk biopolymers using a proprietary fermentation process. The enterprise manufactures biodegradable materials that replicate spider silk proteins to replace petroleum-based plastics and synthetic fibers across the textile, medical device, cosmetics, and aerospace sectors. Operating with 50 to 100 employees, the firm holds over 185 patents for its bio-based products. The organization has secured capital to scale commercialization, including a €29 million Series C round in 2021 and a €25 million extension in 2023 backed by investors like Novo Holdings and Cargill. Its business model relies on direct sales and co-development partnerships with major corporate clients, including Adidas, Airbus, and Evonik Industries. AMSilk was founded in 2008 as a spin-off from the Technical University of Munich by Thomas Scheibel, Lin Römer, and Axel Leimer.
AMSilk has raised $130.8M across 4 funding rounds.
AMSilk has raised $130.8M in total across 4 funding rounds.
AMSilk has raised $130.8M across 4 funding rounds. Most recently, it raised $61.1M Other Equity in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 9, 2025 | $61.1M Venture Round | Daniel Kolb | MIG Capital, Novo Holdings | Announced |
| Apr 4, 2023 | $27.3M Series C Plus | Daniel Kolb | Cargill, MIG Capital, Novo Holdings | Announced |
| May 11, 2021 | $35.3M Series C | Novo Growth | Athos, Asheesh Choudhary, E.r. Capital Holding, Michael Motschmann | Announced |
| Mar 21, 2011 | $7.1M Series B | — | AT NewTec, MIG Fonds | Announced |
AMSilk has raised $130.8M in total across 4 funding rounds.
AMSilk's investors include Daniel Kolb, MIG Capital, Novo Holdings, Cargill, Novo Growth, ATHOS, Asheesh Choudhary, E.R. Capital Holding, Michael Motschmann, AT NewTec, MIG Fonds.
